Literature DB >> 35273358

Mutational signatures and processes in hepatobiliary cancers.

Ekaterina Zhuravleva1, Colm J O'Rourke1, Jesper B Andersen2.   

Abstract

The evolutionary history of hepatobiliary cancers is embedded in their genomes. By analysing their catalogue of somatic mutations and the DNA sequence context in which they occur, it is possible to infer the mechanisms underpinning tumorigenesis. These mutational signatures reflect the exogenous and endogenous origins of genetic damage as well as the capacity of hepatobiliary cells to repair and replicate DNA. Genomic analysis of thousands of patients with hepatobiliary cancers has highlighted the diversity of mutagenic processes active in these malignancies, highlighting a prominent source of the inter-cancer-type, inter-patient, intertumour and intratumoural heterogeneity that is observed clinically. However, a substantial proportion of mutational signatures detected in hepatocellular carcinoma and biliary tract cancer remain of unknown cause, emphasizing the important contribution of processes yet to be identified. Exploiting mutational signatures to retrospectively understand hepatobiliary carcinogenesis could advance preventative management of these aggressive tumours as well as potentially predict treatment response and guide the development of therapies targeting tumour evolution.
© 2022. Springer Nature Limited.

Entities:  

Mesh:

Year:  2022        PMID: 35273358     DOI: 10.1038/s41575-022-00587-w

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   73.082


  176 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 2.  Hepatocellular Carcinoma.

Authors:  Augusto Villanueva
Journal:  N Engl J Med       Date:  2019-04-11       Impact factor: 91.245

Review 3.  Studying the Exposome to Understand the Environmental Determinants of Complex Liver Diseases.

Authors:  Angela C Cheung; Douglas I Walker; Brian D Juran; Gary W Miller; Konstantinos N Lazaridis
Journal:  Hepatology       Date:  2019-12-24       Impact factor: 17.425

4.  Is gallbladder cancer decreasing in view of increasing laparoscopic cholecystectomy?

Authors:  My Di Le; Donald Henson; Heather Young; Jorge Albores-Saavedra
Journal:  Ann Hepatol       Date:  2011 Jul-Sep       Impact factor: 2.400

5.  Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer.

Authors:  Mairéad Geraldine McNamara; Andre Lopes; Harpreet Wasan; David Malka; David Goldstein; Jenny Shannon; Takuji Okusaka; Jennifer J Knox; Anna Dorothea Wagner; Thierry André; David Cunningham; Markus Moehler; Lars Henrik Jensen; Dieter Koeberle; Tanios Bekaii-Saab; John Bridgewater; Juan W Valle
Journal:  J Hepatol       Date:  2020-05-21       Impact factor: 25.083

6.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Authors:  Richard S Finn; Shukui Qin; Masafumi Ikeda; Peter R Galle; Michel Ducreux; Tae-You Kim; Masatoshi Kudo; Valeriy Breder; Philippe Merle; Ahmed O Kaseb; Daneng Li; Wendy Verret; Derek-Zhen Xu; Sairy Hernandez; Juan Liu; Chen Huang; Sohail Mulla; Yulei Wang; Ho Yeong Lim; Andrew X Zhu; Ann-Lii Cheng
Journal:  N Engl J Med       Date:  2020-05-14       Impact factor: 91.245

7.  Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.

Authors:  Paola Bertuccio; Matteo Malvezzi; Greta Carioli; Dana Hashim; Paolo Boffetta; Hashem B El-Serag; Carlo La Vecchia; Eva Negri
Journal:  J Hepatol       Date:  2019-03-23       Impact factor: 25.083

Review 8.  Combined hepatocellular-cholangiocarcinoma: An update.

Authors:  Aurélie Beaufrère; Julien Calderaro; Valérie Paradis
Journal:  J Hepatol       Date:  2021-02-03       Impact factor: 25.083

9.  Gallbladder and extrahepatic bile duct cancers in the Americas: Incidence and mortality patterns and trends.

Authors:  Adalberto Miranda-Filho; Marion Piñeros; Catterina Ferreccio; Volkan Adsay; Isabelle Soerjomataram; Freddie Bray; Jill Koshiol
Journal:  Int J Cancer       Date:  2020-01-21       Impact factor: 7.316

10.  The repertoire of mutational signatures in human cancer.

Authors:  Ludmil B Alexandrov; Jaegil Kim; Gad Getz; Steven G Rozen; Michael R Stratton; Nicholas J Haradhvala; Mi Ni Huang; Alvin Wei Tian Ng; Yang Wu; Arnoud Boot; Kyle R Covington; Dmitry A Gordenin; Erik N Bergstrom; S M Ashiqul Islam; Nuria Lopez-Bigas; Leszek J Klimczak; John R McPherson; Sandro Morganella; Radhakrishnan Sabarinathan; David A Wheeler; Ville Mustonen
Journal:  Nature       Date:  2020-02-05       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.